The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.

CONCLUSIONS: In postmenopausal women with ER+ breast cancer, low CTS5 was considered to be associated with a very low risk of late DR. Thus, extended endocrine therapy may be unnecessary for patients with low CTS5 scores. Extended endocrine therapy should be offered for patients with intermediate or high CTS5 scores, especially those with high-ER and HER2- breast cancer.
PMID: 32601800 [PubMed - as supplied by publisher]

Source: Breast Cancer - June 28, 2020 Category: Cancer & Oncology Authors: Tajiri W, Ijichi H, Takizawa K, Koi Y, Masuda T, Ueo H, Koga C, Nakamura Y, Taguchi K, Okamoto M, Tokunaga E Tags: Breast Cancer Source Type: research